



## BlissCo Completes Pre-Sales License Inspection

### **Not for distribution in the U.S. or to U.S. Newswires**

**Vancouver, British Columbia** – September 25, 2018 – BlissCo Cannabis Corp. (CSE: BLIS) (OTCQB: HSTRF) (FRA: GQ4B), (“BlissCo”) or the (“Company”) is pleased to announce that it has completed Health Canada’s pre-sales license inspection of its Greater Vancouver facility.

BlissCo is a wellness-focused, licensed cannabis producer under the Access to Cannabis for Medical Purposes Regulations (the "ACMPR").

Health Canada inspectors were on site at BlissCo’s facility for a number of days last week to verify information submitted by the Company in its sales license amendment application and also to assess compliance. The Pre-Sales License Inspection is the last step required prior to the issuance of a Sales License under the ACMPR.

“Our experience with Health Canada’s inspectors was highly informative and overall very positive. Their team was incredibly thorough and the entire experience was hugely valuable for our team to experience,” said Damian Kettlewell, CEO of BlissCo Cannabis Corp.” We look forward to receiving our pre-sales license inspection report from Health Canada in early October and earning our sales license for dried cannabis flower in the near future. As well, our team is working diligently to submit our cannabis oil sales license amendment to Health Canada in October.”

The Company also announces that Navdeep Dhaliwal has resigned from BlissCo's board following his appointment to the role of CEO for The Supreme Cannabis Company.

“We'd like to take this opportunity to congratulate Mr. Dhaliwal on his promotion and sincerely thank him for his time on BlissCo's board and for his ongoing support. BlissCo has a two-year supply contract with The Supreme Cannabis Company to purchase 3,000 kilograms of their ultra-premium cannabis. The Supreme team has an unparalleled commitment to ultra-premium cannabis and we are grateful for our partnership,” commented Kettlewell.

## **About BlissCo Cannabis Corp.**

BlissCo Cannabis Corp. (CSE: BLIS) (OTCQB: HSTRF) (FRA: GQ4B) is a wellness-focused, ACMPR licensed producer and future distributor of ultra-premium cannabis. The company sits at the heart of an international ecosystem and is focused on the success of its domestic and global partnerships.

BlissCo leverages the latest technology and is continuously developing its network of top-tier industry experts to drive the success of its brand and channels, moving premium Canadian cannabis to local and international markets.

BlissCo is backed by an experienced team that is deeply in tune and integrated with industry partners and BlissCo's future patients and customers.

Learn more: [BlissCo.com](https://blissco.com)

### **On Behalf of the Board of Directors**

BLISSCO CANNABIS CORP.

Damian Kettlewell, CEO, Founder & Chair

For further information please contact:

Ariel Jack Lewinski, Business Development & Investor Relations

# 1-604-377-7533

[ariel.lewinski@blissco.com](mailto:ariel.lewinski@blissco.com)

### **Cautionary Statement**

This news release contains certain forward-looking information and forward-looking statements within the meaning of applicable securities legislation (collectively “forward-looking statements”). The use of any of the word “will” and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. Such forward-looking statements should not be unduly relied upon. This news release contains forward-looking statements and assumptions pertaining to the

following: the ability to execute on our strategic plans and the impact on our future operations, capital expenditures, receipt of a cannabis oil license and a license to sell dried cannabis and other objectives. Actual results achieved may vary from the information provided herein as a result of numerous known and unknown risks and uncertainties and other factors. The Company believes the expectations reflected in those forward-looking statements are reasonable, but no assurance can be given that these expectations will prove to be correct. The Company does not undertake to update these forward-looking statements, except as required by law.

The CSE has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.